Alpha Teknova (NASDAQ:TKNO – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, Zacks reports. Alpha Teknova had a negative net margin of 55.24% and a negative return on equity of 26.51%. The firm had revenue of $10.45 million for the quarter, compared to the consensus estimate of $10.23 million. Alpha Teknova updated its FY 2025 guidance to EPS.
Alpha Teknova Stock Performance
Alpha Teknova stock opened at $4.81 on Friday. The firm’s fifty day moving average price is $5.09 and its 200-day moving average price is $5.29. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.70 and a current ratio of 5.87. The stock has a market cap of $257.38 million, a P/E ratio of -11.45 and a beta of 0.39. Alpha Teknova has a fifty-two week low of $3.94 and a fifty-two week high of $10.37.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in TKNO. Balyasny Asset Management L.P. raised its position in Alpha Teknova by 19.5% during the second quarter. Balyasny Asset Management L.P. now owns 1,000,484 shares of the company’s stock valued at $4,912,000 after purchasing an additional 163,526 shares in the last quarter. Massar Capital Management LP increased its position in shares of Alpha Teknova by 185.7% during the 2nd quarter. Massar Capital Management LP now owns 200,000 shares of the company’s stock valued at $982,000 after purchasing an additional 130,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Alpha Teknova by 64.4% during the 2nd quarter. Geode Capital Management LLC now owns 298,850 shares of the company’s stock valued at $1,468,000 after buying an additional 117,016 shares in the last quarter. Marshall Wace LLP lifted its position in Alpha Teknova by 83.0% in the 2nd quarter. Marshall Wace LLP now owns 90,032 shares of the company’s stock worth $442,000 after buying an additional 40,825 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Alpha Teknova by 68.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company’s stock worth $470,000 after buying an additional 36,763 shares during the last quarter. Institutional investors own 13.81% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on TKNO
Alpha Teknova Company Profile
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Further Reading
- Five stocks we like better than Alpha Teknova
- How to Short a Stock in 5 Easy Steps
- Why Investors Shouldn’t Fear the Dip in Microsoft Stock
- Best Aerospace Stocks Investing
- DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave
- What is the Dogs of the Dow Strategy? Overview and Examples
- CAVA Stock Looking for Direction After Earnings Miss
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
